Catalyst Science Discovery Centre appoints director

Widnes, Cheshire-based firm welcomes Stephen Youd-Thomas

Catalyst Science Discovery Centre, an interactive science centre and museum devoted to chemistry and how the products of chemistry are used in everyday life based in Widnes, Cheshire, UK, has a new director of catalyst, which encompasses the role of ERDF project director.

Stephen Youd-Thomas runs a successful corporate and social responsibility consultancy and was formerly head of social goals at the Co-operative Group.

‘This is a wonderful opportunity to help develop the work of the UK's only science discovery centre with chemistry as its main theme. Catalyst brings chemistry alive for thousands of young people from across the North West and beyond and hopefully this experience will encourage many of them to consider a career in science in the future,’ he said.

Catalyst is an independent charitable trust operated by Catalyst Science Discovery Centre and Museum Trust.

You may also like

Regulatory

MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results

The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Manufacturing

Roquette opens pharmaceutical innovation centre in Brazil

The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
Manufacturing

RHEOFREED: A game-changing innovation in lyophilization technology

Dec Group announces its partnership with Kobelco Eco Solutions, Japan, and presents RHEOFREED®, a revolutionary mixer-type freeze dryer at CPHI Frankfurt 2025
Manufacturing

Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours

The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Manufacturing

Merck breaks ground on $3bn US manufacturing centre

The 400,000 sqft Elkton expansion forms part of Merck’s $70bn US investment plan to bolster domestic pharmaceutical manufacturing and R&D, creating more than 500 new full-time roles
Research & Development

AlzeCure Pharma publishes response letter clarifying Alzstatin’s distinct mechanism in Alzheimer’s treatment

AlzeCure Pharma and leading academic collaborators have published a response in JPET addressing recent commentary on Alzstatin’s γ-secretase modulation data, reaffirming the promise of lead candidate ACD680 in Alzheimer’s therapy
Regulatory

NAD+ supplement claims under scrutiny as Niagen Bioscience wins landmark advertising case

The National Advertising Division (NAD) has ruled against Reus Research over unsupported NAD+ product claims, reinforcing that oral NAD+ ingestion lacks scientific backing and affirming Niagen’s clinically proven approach
Subscribe now